Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 11/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 10/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130339 | 1.00 | NAPEPLD (0.49) | NAPEPLDBRAFMCHR1TACR1GAA | |
| SCHEMBL30795212 | 0.90 | TP53 (0.47) | NAPEPLDGAALMNAPIK3CA | |
| SCHEMBL2129915 | 0.90 | TP53 (0.47) | NAPEPLDGAALMNAPIK3CA | |
| SCHEMBL2131268 | 0.88 | KMT2A (0.51) | NAPEPLDLMNAPIK3CA | |
| SCHEMBL30795446 | 0.88 | KMT2A (0.51) | NAPEPLDLMNAPIK3CA | |
| SCHEMBL2130581 | 0.86 | PPARG (0.47) | NAPEPLDLMNAPIK3CA | |
| SCHEMBL30794475 | 0.86 | PPARG (0.47) | NAPEPLDLMNAPIK3CA | |
| SCHEMBL19712385 | 0.85 | NAPEPLD (0.48) | NAPEPLDBRAFMCHR1GAARAF1 | |
| SCHEMBL30795292 | 0.85 | NAPEPLD (0.42) | NAPEPLDBRAFLMNARAF1PIK3CA | |
| SCHEMBL2131151 | 0.85 | NAPEPLD (0.42) | NAPEPLDBRAFLMNARAF1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |